Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Ethylenediamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALPI | P09923 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylenediamine SCHEMBL7109144 | 1.00 | ADRA2C (0.40) | ADRA2CNPSR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL449666 | 0.90 | NPSR1 (0.44) | NPSR1LMNAMAPK1ALDH1A1KMT2A | |
| SCHEMBL449664 | 0.90 | NPSR1 (0.44) | NPSR1LMNAMAPK1ALDH1A1KMT2A | |
| SCHEMBL329145 | 0.71 | NPSR1 (0.41) | NPSR1SLC1A3SLC1A2SLC1A1LMNA | |
| SCHEMBL9283942 | 0.71 | NPSR1 (0.41) | NPSR1SLC1A3SLC1A2SLC1A1LMNA | |
| SCHEMBL329144 | 0.71 | NPSR1 (0.41) | NPSR1SLC1A3SLC1A2SLC1A1LMNA | |
| SCHEMBL9283953 | 0.71 | NPSR1 (0.41) | NPSR1SLC1A3SLC1A2SLC1A1LMNA | |
| SCHEMBL9283956 | 0.71 | NPSR1 (0.41) | NPSR1LMNAMAPK1ALDH1A1KMT2A | |
| SCHEMBL329146 | 0.71 | NPSR1 (0.41) | ADRA2CNPSR1LMNAMAPK1ALDH1A1 | |
| SCHEMBL11569052 | 0.69 | TSHR (0.41) | ADRA2CNPSR1SLC1A2LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.) | 2011-07-21 | — | — | US | claimed |
| EP-2451776-B1 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | LANTHEUS MEDICAL IMAGING INC (US) | 2019-09-18 | — | — | EP | disclosed |
| US-9732047-B2 | N-alkoxyamide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| EP-2240206-B1 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | LANTHEUS MEDICAL IMAGING INC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20170029386-A9 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-02-02 | — | — | US | disclosed |
| US-9393329-B2 | N-alkoxyamide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160185737-A1 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-9266846-B2 | N-alkoxyamide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9217009-B2 | Version of FDG detectable by single-photon emission computed tomography | MALLINCKRODT LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150094465-A1 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| EP-0888130-A2 | NEW TERNARY RADIOPHARMACEUTICAL COMPLEXES | Du Pont Pharmaceuticals Company (US) | 1999-01-07 | — | — | EP | disclosed |
| US-5750088-A | IMAGING AGENTS FOR DIAGNOSIS OF CARDIOVASCULAR DISORDERS,INFECTIONS, INFLAMMATION, CANCER | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-05-12 | — | — | US | disclosed |
| US-5744120-A | PHOSPHINE OR ARSINE LIGATED TECHNETIUM-99M LABELED HYDRAZINO OR DIAZINO MODIFIED BIOLOGICALLY ACTIVE MOLECULES THAT SELECTIVELY LOCALIZE AT SITES OF DISEASE | THE DUPONT MERICK PHARMACEUTICAL COMPANY (US) | 1998-04-28 | — | — | US | disclosed |
| WO-1998015295-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-04-16 | — | — | WO | disclosed |
| EP-0832068-A1 | STABLE REAGENTS FOR THE PREPARATION OF RADIOPHARMACEUTICALS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0820312-A4 | TERNARY RADIOPHARMACEUTICAL COMPLEXES | DU PONT MERCK PHARMA (US) | 1998-03-18 | — | — | EP | disclosed |
| EP-0820312-A1 | TERNARY RADIOPHARMACEUTICAL COMPLEXES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-01-28 | — | — | EP | disclosed |
| WO-1997033627-A2 | NEW TERNARY RADIOPHARMACEUTICAL COMPLEXES | DU PONT PHARMACEUTICALS COMPANY (US) | 1997-09-18 | — | — | WO | disclosed |
| WO-1996040637-A1 | STABLE REAGENTS FOR THE PREPARATION OF RADIOPHARMACEUTICALS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996031243-A1 | TERNARY RADIOPHARMACEUTICAL COMPLEXES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | SLC2A1, SLC2A4, SLC2A3 | ADRA2C 3433/4885NPSR1 4448/4885SLC1A3 193/4885 |
| US-20150094465-A1 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | TNNT2, UACA, ELANE | ADRA2C 3006/4885NPSR1 463/4885SLC1A3 2655/4885 |
| US-20170029386-A9 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | TNNT2, UACA, ELANE | ADRA2C 3006/4885NPSR1 463/4885SLC1A3 2655/4885 |
| US-20160185737-A1 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | TNNT2, UACA, ELANE | ADRA2C 3006/4885NPSR1 463/4885SLC1A3 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.